Ricardo: UK Consortium to Deliver World’s First Truly Green Passenger Carrying Airline Services Using Hydrogen Fuel Cell Technology
30.3.2021 02:01:00 EEST | Business Wire | Press release
Cranfield Aerospace Solutions (CAeS) - the UK SME leading the Project Fresson consortium - announces it will exploit recent advances in hydrogen fuel cell technology to develop a commercially viable, retrofit powertrain solution for the nine-passenger Britten-Norman Islander aircraft.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210329005667/en/
Project Frisson to deliver world's first green passenger aircraft service (Graphic: Business Wire)
Following a rigorous assessment of hydrogen technology innovators, CAeS is delighted to welcome Ricardo UK Ltd and Innovatus Technologies Ltd to the Fresson consortium. Ricardo UK Ltd brings expertise in fuel cell system development and Innovatus Technologies Ltd brings their innovative Scottish Hydrogen Fuel Tank (SHyFT) technology.
Steve Dyke, Managing Director Ricardo Automotive and Industrial EMEA Division said: “We are proud to join the Cranfield Aerospace Solutions consortium to play our part in helping to reduce the carbon footprint for commercial air passengers. We are already working on hydrogen and fuel cell technology, providing clean efficient solutions which reduce carbon and noxious emissions across a wide range of sectors. Our work for the Fresson consortium will enable us to consolidate and grow our hydrogen fuel cell and propulsion capability, so that Ricardo can achieve its ambition of becoming a world-leader in hydrogen and fuel cell services and solutions and help accelerate net zero transportation.”
Innovatus Technologies Ltd leads the field in next generation ultralightweight hydrogen tank design exploiting patented cellular core composite techniques. This is critical to the successful integration and exploitation of hydrogen fuel cell power systems in applications across aerospace, automotive, industrial, and marine sectors.
Ruan Swart, Chief Executive Officer Innovatus Technologies Ltd said: ““We are proud in being selected to join the Cranfield Aerospace Solutions, ‘Project Fresson’, consortium. Our unique and innovative SHyFT solution is game-changing in bringing zero carbon fuel cell energy to commercial reality in the transport sector. Project Fresson showcases important Scottish innovation and next generation hydrogen tank manufacturing in the UK.”
Project Fresson will deliver an emissions-free (zero CO2), hydrogen-fuel-cell-powered flying demonstrator by September 2022. Having completed a comprehensive evaluation of technologies and configurations for sustainable aircraft propulsion, the Fresson team concluded that hydrogen fuel cell technology is the optimum solution to meet environmental, regulatory and operational requirements for this size of aircraft, enabling zero carbon emissions and reducing operating costs. This has presented the Fresson consortium, which includes Britten-Norman and Cranfield University, with an opportunity to deliver an enhanced technology programme that surpasses the original demonstrator concept.
Paul Hutton, Chief Executive Officer, Cranfield Aerospace Solutions said: “This is incredibly important for the Project Fresson Team but also for everyone else around the world interested in zero emissions flight. This project can deliver the world’s first truly “green” passenger carrying airline services. The whole team is proud of what Project Fresson has achieved so far and excited about what is to come. I am very thankful for the support of the ATI and our investors for making this ground-breaking work a reality.”
Jenny Kavanagh, Chief Strategy Officer, Cranfield Aerospace Solutions added: “Covid-19 has caused the biggest crisis in aviation’s history. It’s important that, as the sector builds back better, it does so with sustainability at its heart. Project Fresson is more than just a technology demonstrator; it has one focus above all others: real operational and commercial viability.”
Project Fresson is supported by the ATI Programme, a joint Government and industry investment to maintain and grow the UK’s competitive position in civil aerospace design and manufacture. The programme, delivered through a partnership between the Aerospace Technology Institute (ATI), Department for Business, Energy & Industrial Strategy (BEIS) and Innovate UK, addresses technology, capability and supply chain challenges.
As a result of these changes, there is now no longer a need for the Rolls-Royce element of the aircraft programme. It is therefore Rolls-Royce’s intention to withdraw from Project Fresson and the consortium is going through the necessary steps for this to happen. We thank Rolls-Royce for its contribution to Project Fresson and wish its team well. Rolls-Royce will continue to actively research the use of hydrogen in aviation and this decision in no way reflects its overall view of hydrogen as a potential technology.
Ends
Notes to editors
- To follow the progress of Project Fresson, visit the microsite: www.projectfresson.uk or follow on Twitter @projectfresson.
- Cranfield Aerospace Solutions (CAeS) is an aerospace market leader in rapid prototyping of new aerospace concepts, modifications to existing aerospace platforms and integration of cutting-edge technologies to meet the most challenging issues facing the industry today. CAeS is the wholly owned commercial arm of Cranfield University. Visit: www.cranfieldaerospace.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210329005667/en/
Contact information
Media contacts
For Cranfield Aerospace Solutions:
Telephone: +44 (0) 1234 754046
Email: enquiries@cranfieldaerospace.com
For Ricardo
Kathryn Bellamy
Communications Manager
Ricardo Automotive & Industrial EMEA Division, and Performance Products Division
Email: kathryn.bellamy@ricardo.com
Telephone: +44(0)7921 941824
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom